Nucynta ER extended-release tablets were significantly more effective than a placebo in providing pain relief to adults with chronic diabetic peripheral neuropathy, according to a News-Medical report.
Among patients who had at least a one-point reduction in pain intensity during three weeks of treatment with tapentadol ER, those who continued on a 100 to 250 mg twice-daily dose for an additional 12 weeks experienced significantly better pain control compared to those who switched to a placebo, the study found.
Adverse effects among these patients included nausea (21.1 percent) and vomiting (12.7 percent).
Athletes' Higher Pain Tolerance May Pave Way for Pain Management Research
New Treatment Uses IV Injections for Severe Migraines
Among patients who had at least a one-point reduction in pain intensity during three weeks of treatment with tapentadol ER, those who continued on a 100 to 250 mg twice-daily dose for an additional 12 weeks experienced significantly better pain control compared to those who switched to a placebo, the study found.
Adverse effects among these patients included nausea (21.1 percent) and vomiting (12.7 percent).
Related Articles on Pain Management:
Study Targets Effective Adolescent Migraine ReliefAthletes' Higher Pain Tolerance May Pave Way for Pain Management Research
New Treatment Uses IV Injections for Severe Migraines